Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conservative surgery plus dabrafenib/trametinib for BRAF V600E-mutant ameloblastoma
ChiCTR2500106861Phase 2Not yet recruiting
- Sponsor
- Affiliated Stomatological Hospital of Sun Yat-Sen University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in ameloblastoma, sponsored by Affiliated Stomatological Hospital of Sun Yat-Sen University. Primary endpoints: Objective Response Rate (ORR) of BRAFV600E-mutant ameloblastoma and Mandibular preservation rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
ameloblastoma
Beyond the preview
Go deeper on ChiCTR2500106861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106861.